Besides the two lead product candidates (MB 311 and MB 314), Meridian Biopharmaceuticals also pursues exploratory projects. This portfolio comprises the multi-epitope anti-cancer vaccination technology, a gene delivery approach and a new technology platform for identification of tumor specific antibodies.